Skip to main content
Fig. 5 | BMC Rheumatology

Fig. 5

From: Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

Fig. 5

B cell maturation is prevented by lanraplenib in the spleens of NZB/W mice. a Schematic of B cell maturation in the spleen. Surface markers used in this study to define each phase of B cell maturation are shown. b Representative flow cytometry gating scheme. c Geometric mean (± geo standard deviation) of the abundance of immature B cells (left), plasma cells (middle), and Tfh cells (right) within the spleens of mice at the end of the study. Cell counts were normalized to spleen mass. Each point represents an individual mouse. Statistics were calculated comparing the vehicle control group to each other group using either an ANOVA or Kruskal-Wallis test. *Indicates P < 0.05. ***Indicates P < 0.0005

Back to article page